Does PFNA exposure cause oxidative stress and liver injury signals?

Perfluoroalkyl substances (PFAS), particularly perfluorononanoic acid (PFNA), are persistent environmental contaminants increasingly linked to metabolic and hepatic dysfunction. Research across human cohorts and experimental models indicates that PFNA exposure is a significant driver of cellular stress and clinical markers of liver damage.

Mechanistic evidence for oxidative stress

Evidence strongly supports the association between PFNA and oxidative stress, primarily mediated through mitochondrial impairment and nuclear receptor activation.

• PFNA exposure significantly elevates reactive oxygen species (ROS) and biomarkers of oxidative damage, such as 8-isoprostaglandin F2α metabolite (IsoP-M) and 8-isoprostane.
• Mechanistically, PFNA activates the peroxisome proliferator-activated receptor alpha (PPARα), which disrupts energy metabolism and impairs mitochondrial enzymes like pyruvate dehydrogenase.
• This leads to a loss of mitochondrial membrane potential and overwhelms cellular antioxidant defenses (e.g., catalase and glutathione reductase), triggering downstream DNA damage, early-stage apoptosis, and ferroptosis.

Clinical evidence for liver injury

Population-level data and experimental studies provide a plausible link between PFNA exposure and signals of liver injury.

• Meta-analyses of human epidemiological data, including the C8 Health Study and representative U.S. samples from NHANES, demonstrate a significant positive association between PFNA levels and elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
• Longitudinal data from the Wuxi Birth Cohort further confirm these associations with clinical biomarkers of hepatocyte damage and apoptosis (e.g., cytokeratin 18 M30).
• Experimental models, including multi-donor human liver spheroids and rodent studies, show that PFNA promotes lipid disruption and steatosis. While associations with complex diseases like NAFLD vary, the elevation of individual injury markers (ALT/AST) remains a consistent finding across diverse age groups.

Bottom line

PFNA exposure is robustly associated with oxidative stress and is a plausible contributor to clinical liver injury signals. These findings suggest that PFAS exposure can exacerbate cellular oxidative burden and contribute to subclinical elevations in liver enzymes, particularly through mitochondrial and PPARα-mediated pathways.